These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. Brandts J; Ray KK Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965 [TBL] [Abstract][Full Text] [Related]
8. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005 [TBL] [Abstract][Full Text] [Related]
9. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. German CA; Shapiro MD BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112 [TBL] [Abstract][Full Text] [Related]
10. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Arnold N; Koenig W Curr Cardiol Rep; 2022 Nov; 24(11):1657-1667. PubMed ID: 36087240 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Tomlinson B; Chow E; Chan P; Lam CWK Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1353-1361. PubMed ID: 35025707 [TBL] [Abstract][Full Text] [Related]
14. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. Kam N; Perera K; Zomer E; Liew D; Ademi Z Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593 [TBL] [Abstract][Full Text] [Related]
15. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484 [TBL] [Abstract][Full Text] [Related]
16. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492 [TBL] [Abstract][Full Text] [Related]
17. [Inclisiran - a new era in lipid-lowering therapy]. Voevoda MI; Gurevich VS; Ezhov MV; Sergienko IV Kardiologiia; 2022 Jun; 62(6):57-62. PubMed ID: 35834343 [TBL] [Abstract][Full Text] [Related]
18. Inclisiran: A Game Changer in a Changing Game? Nambi V; Agha A J Am Coll Cardiol; 2021 Mar; 77(9):1194-1196. PubMed ID: 33663736 [No Abstract] [Full Text] [Related]
19. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering. Soffer D; Stoekenbroek R; Plakogiannis R J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047 [TBL] [Abstract][Full Text] [Related]
20. Inclisiran: A Review in Hypercholesterolemia. Frampton JE Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]